Pharmacokinetics of albendazole in New Zealand white rabbits: Oral versus intraperitoneal administration

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 417-422

  Cai, Zhao Yan ^a   Galettis, Peter ^a   Lu, Ying ^a   Morris, David L ^a   Pourgholami, Mohammad H ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Albendazole; Albendazole sulphoxide; Peritoneal carcinomatosis

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFOXIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CARCINOMATOSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; RABBIT; SINGLE DRUG DOSE; TUMOR CELL;

ADMINISTRATION, ORAL; ALBENDAZOLE; ANIMALS; ANTINEOPLASTIC AGENTS; INJECTIONS, INTRAPERITONEAL; MALE; RABBITS; RANDOM ALLOCATION;

EID: 33847619893     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pilati P, Rossi CR, Mocellin S, Foletto M, Scagnet B, Pasetto L and Lise M: Multimodel treatment of peritoneal carcinomatosis and sarcomatosis. EJSO 27: 125-134, 2001.
2. Weisberger AS, Levine B and Storaasli JP: Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 159: 1704-1707, 1955.
3. Marchettini P, Stuart OA, Mohamed F, Yoo D and Sugarbaker PH: Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 49: 499-503, 2002.
4. Mohamed F, Marchettini O, Stuart OA and Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol 52: 405-410, 2003.
5. Glehen O, Mithieux F and Osinsky AC: Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol 21: 799-806, 2003.
6. Sugarbaker PH: Management of peritoneal surface malignancy: the surgeon's role. Langenbecks Arch Surg 384: 576-587, 1999.
7. Marriner SE, Morris DL, Dickson B and Bogan JA: Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 30: 705-708, 1986.
8. Rawden HL, Kokwaro GO, Ward SA and Edwards G: Relative contribution of cytochromes P450 and flavin-containing monooxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 49: 313-32, 2000.
9. Lacey E and Watson TR: Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: correlation with in vitro tubulin polymerization assay. Biochem Pharmacol 34: 3603-3605, 1985.
10. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P and Morris DL: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 165: 43-49, 2001.
11. Pourgholami MH, Akhter J, Wang L, Lu Y and Morris DL: Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 55: 425-432, 2005.
12. Pourgholami MH, Cai ZY, Lu Y, Wang LX and Morris DL: Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 12: 1928-1935, 2006.
13. Gatltier P, Alvinerie M and Delatour P: In vitro sulphoxidation of albendazole by ovine liver microsomes. Am J Vet Res 47: 447-450, 1986.
14. Merino G, Molina AJ, Garcia L, Pulido MM, Prieto JG and Alvarez AI: Effect of clotrimazole on microsomal metabolism and pharmacokinetics of albendazole. J Pharm Pharmacol 55: 757-764, 2003.
15. Alvarez LI, Sanchez SF and Lanusse CE: In vivo and ex vivo uptake of albendazole and its sulphoxide metabolite by cestode parasites: relationship with their kinetic behaviour in sheep. J Vet Pharmacol Ther 22: 77-86, 1999.
16. Prieto JG, Justel A, Del Estal JL, Barrio JP and Alvarez AI: Comparative study on gastric absorption of albendazole and mebendazole in rats. Comp Biochem Physiol 100C: 397-400, 1991.
17. Jung H, Medina L, Fuentes I and Moreno-Esparza R: Absorption studies of albendazole and some physiochemical properties of the drug and its metabolite albendazole sulphoxide. J Pharm Pharmcol 50: 43-48, 1998.
18. Mottier ML, Alvarez LI, Pis MA and Lanusse CE: Transtegumental diffusion of benzimidazole anthelmintics into Moniezia benedeni: correlation with their octanol- water partition coefficients. Exp Parasitol 103: 1-7, 2003.
19. Markman M: Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4: 277-283, 2003.
20. Zakaria E, Simonsen O, Rippe A and Rippe J: Transport of tracer albumin from peritoneum to plasma: role of diaphragmatic, visceral and parietal lymphatics. Am J Physiol 270: H1549-H1556, 1996.
21. Sadzuka Y, Hirama R and Sonobe T: Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy. Toxicol Lett 126: 83-90, 2002.
22. Lawrenz A, Eglit S and Kroker R: The metabolism of albendazole in the isolated perfused intestine of rats. Deutsche Tierarztliche Wochenschrift 99: 416-418, 1992.
23. Redondo PA, Alvarez AI, Garcia JL, Larrode OM, Merino G and Prieto JG: Presystemic metabolism of albendazole: experimental evidence of an efflux process of albendazole sulfoxide to intestinal lumen. Drug Metab Dispos 27: 736-740, 1999.
24. Rawden HL, Kokwaro GO, Ward SA and Edwards G: Relative contribution of cytochromes P450 and flavin-containing monooxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 49: 313-322, 2000.
25. Marriner SE, Morris DL, Dickson B and Bogan JA: Pharmacokinetics of albendazole in man. EurJ Clin Pharmacol 30: 705-708, 1986.